Form 4: Zenas BioPharma Grants 100,000 Stock Options to Chief Commercial Officer Orlando Oliveira

Zenas BioPharma, Inc. has granted 100,000 stock options to its Chief Commercial Officer, Orlando Oliveira, with an exercise price of $11.94 per share, vesting over four years.

Summary

• Orlando Oliveira, the Chief Commercial Officer of Zenas BioPharma, Inc. (ZBIO), was granted 100,000 stock options.
• The stock options have an exercise price of $11.94 per share.
• The options will vest as to 25% of the underlying shares on June 10, 2026, which is the first anniversary of the vesting commencement date.
• The remaining shares will vest in equal monthly installments over 36 months thereafter, contingent upon continued service.
• The expiration date for these stock options is June 10, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's interests with long-term shareholder value and aids in executive retention. This is a routine compensation event and does not indicate operational issues.

Positives

• The grant of 100,000 stock options to a key executive like Orlando Oliveira aligns his long-term interests with those of the shareholders.
• The multi-year vesting schedule encourages executive retention and continued commitment to the company's performance.

Future Outlook

The vesting schedule for the granted stock options extends over four years, indicating an expectation of continued service from the Chief Commercial Officer through at least June 2029, aligning executive incentives with long-term company performance.

Management Comments

• The grant of stock options to the Chief Commercial Officer reflects the company's compensation strategy to incentivize and retain key executives, aligning their interests with shareholder value.

Industry Context

The granting of stock options is a standard practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize executive talent, aligning their performance with long-term company growth and shareholder interests.

Comparison to Industry Standards

• Stock option grants with multi-year vesting schedules are a common component of executive compensation packages across various industries, including biotechnology, designed to promote long-term commitment and performance alignment.

Related Party Transactions

• Grant of 100,000 stock options to Orlando Oliveira, the Chief Commercial Officer, by Zenas BioPharma, Inc., which constitutes a transaction between the company and a related party (executive officer).

Stakeholder Impact

• Shareholders: Potential long-term alignment of executive interests with shareholder value; potential future dilution if options are exercised.
• Employees: May signal stability in executive leadership and a commitment to incentivizing key personnel.

Next Steps

• Orlando Oliveira's stock options will begin vesting on June 10, 2026, with subsequent monthly vesting over the following 36 months, subject to his continued service.

Key Dates

Keywords

Zenas BioPharma, ZBIO, stock options, executive compensation, Orlando Oliveira, Chief Commercial Officer, SEC Form 4, beneficial ownership